Infectiology & Clinical Microbiology
Urine culture - ECBU
Urine cytobacteriological examination (UCE), commonly referred to as urine culture in North America, is the microbiological reference test for diagnosing and characterizing urinary tract infections (UTIs) - acute cystitis, acute pyelonephritis, male urinary tract infection (prostatitis), catheter-acquired UTI and asymptomatic bacteriuria. It combines three complementary analyses on a single sample: cytological examination (leukocyte and erythrocyte count in cells per milliliter), quantitative culture (identification of the microorganism(s) and count in colony-forming units per milliliter - CFU/mL) and antibiogram (antibiotic susceptibility profile of the isolated germ), enabling not only confirmation or invalidation of the infection, but also guiding the choice of optimal antibiotic therapy. Interpretation of a UTI requires simultaneous assessment of three interdependent factors - the quality of the sample (collection technique, transit time), the cytological results (leukocyturia and hematuria) and the bacteriological results (quantitative bacteriuria, nature of the germ, antibiogram) - in the patient's clinical context (symptoms, sex, age, pregnancy, risk factors for complicated UTIs, history of recurrent urinary tract infections, urological instrumentation). Diagnostic thresholds for significant UTIs vary according to population, sampling method and germ isolated - isolated bacteriuria without leukocyturia, or isolated leukocyturia without bacteriuria, does not necessarily mean infection and should not systematically lead to antibiotic therapy, particularly in the context of asymptomatic bacteriuria - one of the most frequent causes of unnecessary antibiotic overprescription.
Sampling technique - reliability requirements
- Collection of the median jet (standard method): after careful genital cleansing (antiseptic wipe supplied or soap and water) - in women: part the labia majora, clean the vulva from front to back; in men: decalcify, clean the glans; discard the first urine jet (20 mL) - mechanically wash the urethra - then collect the median jet directly in the sterile jar supplied without interrupting micturition; close immediately; do not contaminate the inside rim of the jar.
- First morning's urine: ideally collected on waking - urine that has been in the bladder for at least 4 hours, concentrating bacteria if present; if this is not possible, the urine must have been in the bladder for at least 2 hours before sampling.
- Transit time: analyze within 2 hours of sampling at room temperature; if > 2 hours: refrigerate at 4°C (maximum 24 hours) or use a tube with boric acid (preservative - stabilizes flora for up to 48 hours at room temperature); excessive delay at room temperature leads to in vitro bacterial multiplication → false positivity of the culture
- Special samples: in-out bladder catheterization (suprapubic or transurethral catheterization for medical indication) - reference method for patients unable to provide a reliable median jet (obese women, dependent elderly people, neurological patients) - avoids perineal contamination; suction at indwelling catheter sampling site - never sample from the collection bag (systematic contamination); suprapubic sampling by direct bladder puncture - gold standard for infants and in case of doubt about contamination
- Urine dipstick (UD) as an adjunct or triage: detects leukocytes (leukocyte esterase) and nitrite-producing bacteria (enterobacteria - enterobacteria). E. coli, Klebsiella, Proteus); sensitivity 80-90 %, specificity 70-80 % for UTI; a negative BU (leucocyte esterase and nitrite both negative) has a high negative predictive value (> 95 %) and allows UTI to be avoided in uncomplicated cystitis in young women in the absence of signs of complication; the BU does not replace the ECBU if clinical suspicion is high despite a negative BU, or if information on the germ and its sensitivity is required (pyelonephritis, recurrence, pregnancy, men).
Diagnostic thresholds for ECBU
| Population / Background | Leukocyturia (cells/mL) | Bacteriuria (CFU/mL) | Remarks |
|---|---|---|---|
| Symptomatic women (cystitis) | ≥ 10 000 | ≥ 1 000 | Lowered bacteriuria threshold in symptomatic women - bacteriuria ≥ 1,000 CFU/mL with leukocyturia and typical symptoms is sufficient to treat ; E. coli in 80-85 % cystitis cases |
| Symptomatic man | ≥ 10 000 | ≥ 1 000 | Any male urinary tract infection is considered complicated - urological assessment recommended after a first episode; prostatitis must be systematically evoked; ; E. coli predominant, but enterococcus more common than in women |
| Pregnancy (asymptomatic bacteriuria) | ≥ 10 000 | ≥ 100 000 | Mandatory treatment of asymptomatic bacteriuria in pregnancy - risk of pyelonephritis (30 %) and premature delivery; systematic screening at 12-16 weeks of pregnancy recommended in Canada |
| Acute pyelonephritis | ≥ 10 000 | ≥ 10 000 | Lowered threshold acceptable; blood cultures recommended in parallel if fever ≥ 38.5 °C or chills ; E. coli in 80 % of community-acquired pyelonephritis |
| Indwelling bladder catheter (UTI on catheter) | ≥ 10 000 | ≥ 100 000 | Asymptomatic bacteriuria on catheter is universal after 30 days - do not treat except for symptoms, pregnancy, before urological manipulation or transplantation; multiple germs and frequent resistance (Pseudomonas, Klebsiella BLSE, Enterococcus, Candida) |
| Children (> 2 years) | ≥ 10 000 | ≥ 100 000 | Median jet sampling or catheterization in young children; bacteriuria threshold identical to that in adults; always consider an anatomical anomaly of the urinary tract after a first episode (vesicoureteral reflux). |
| Infant (< 2 years) | ≥ 10 000 | ≥ 50 000 | Sampling by suprapubic puncture or reference urinary catheterization (highly contaminated adhesive collector); lower threshold for suprapubic puncture: any bacteriuria is significant |
| Asymptomatic bacteriuria (non-pregnant adults) | Variable | ≥ 100 000 × 2 | Two separate samples taken 24-48 hours apart with the same germ at the same threshold - formal definition; does not require treatment in non-pregnant adults except before urological instrumentation or urinary surgery. |
Most common germs and resistance profiles in Quebec
| Microorganism | Frequency UTI comm. | Resistance profile and key points |
|---|---|---|
| Escherichia coli | 75-85 % | First agent of community-acquired UTIs; resistance to TMP-SMX ≈ 15-20 % in Quebec (threshold of 20 % recommending empirical use of another antibiotic); resistance to fluoroquinolones ≈ 10-15 %; susceptible to nitrofurantoin (95 %), fosfomycin (98 %) and 2nd-generation cephalosporins ; E. coli ESBL (extended spectrum beta-lactamase) - 3-7 % community strains - resistant to 3rd generation cephalosporins, imipenem required in severe forms |
| Klebsiella pneumoniae | 5-8 % | Intrinsic resistance to aminopenicillins; ESBL on the rise (5-10 % of community strains); KPC (carbapenemase-producing Klebsiella) strains - rare but emerging - resistant to almost all antibiotics. |
| Staphylococcus saprophyticus | 5-10 % (young woman) | Second cause of cystitis in sexually active young women (15-30 years); sensitive to nitrofurantoin, cephalosporins and TMP-SMX; intrinsic resistance to fosfomycin (variable); resistance to TMP-SMX < 5 % |
| Proteus mirabilis | 3-5 % | Characteristic ammoniacal odor (urease+); alkalinizes urine → struvite stones; intrinsic resistance to nitrofurantoin and tetracycline; sensitive to aminopenicillins (ampicillin), cephalosporins and fluoroquinolones |
| Enterococcus faecalis | 2-5 % | More common in men (prostatitis), the elderly and catheterized patients; intrinsic resistance to cephalosporins and aminoglycosides (monotherapy); treatment: amoxicillin or nitrofurantoin; vancomycin-resistant enterococci (VRE) rare in the community but a concern in hospitals. |
| Pseudomonas aeruginosa | < 2 % comm. / 10-15 % hospital. | Practically exclusive to nosocomial UTIs, catheterized patients, immunocompromised patients, cystic fibrosis; multiple natural and acquired resistances; treatment: ciprofloxacin (if sensitive), piperacillin-tazobactam, cefepime, imipenem according to antibiogram. |
| Candida spp. | Rare comm. / frequent hospital. | Candiduria often colonized (urinary catheter, antibiotics, diabetes, resuscitation) - treatment rarely indicated except before urological surgery, neutropenia, kidney transplantation or newborns; ; C. albicans sensitive to fluconazole; ; C. glabrata / C. krusei variable resistors |
ℹ️
Sample contamination is the leading cause of false-positive ECBU results. It is suspected if: several germs are present (≥ 2 different species in significant concentration); germs that are usually commensal (lactobacilli, coagulase-negative staphylococci other than those listed above, etc.) are present. S. saprophyticus, corynebacteria); leukocyturia absent despite high bacteriuria; or bacteriuria at the limit of the threshold. In these situations, a second sample is recommended before treatment, particularly in the absence of symptoms.
Interpretation according to clinical picture
- Simple acute cystitis (young, non-pregnant woman, no risk factors): clinical diagnosis often sufficient (dysuria + pollakiuria + mictional burning without fever, without lumbar pain) - empirical antibiotic treatment without systematic ECBU according to NICE 2023 and INESSS recommendations; BU negative on both criteria (esterase + nitrite) - diagnosis of cystitis unlikely, reassess; first-line antibiotic treatment: nitrofurantoin 100 mg × 2/day × 5 days (Macrobid) - very low resistance rate (< 5 % in North America), well tolerated, local bladder action without systemic selection pressure, avoid if GFR < 45 mL/min; TMP-SMX 160/800 mg × 2/day × 3 days (Septra, Bactrim) - if local resistance rate < 20 % ; fosfomycin 3 g single dose - excellent activity, single dose favors adherence, active against ESBL; fluoroquinolones (ciprofloxacin) - reserve for complicated infections or after antibiotic susceptibility testing (preserve this class)
- Recurrent cystitis (≥ 3 episodes/year or ≥ 2 episodes/6 months): systematic ECBU before each treatment; antibiogram to adapt antibiotic therapy; look for favouring factors (sexual activity, spermicidal contraception, anatomy, menopause, prolapse, diabetes, urological anomaly); non-antibiotic prophylactic measures: hydration 1.5-2 L/day, urination after intercourse, cessation of spermicides, complete micturition, local estrogens in post-menopause (50 % reduction in recurrences); cranberry (D-mannose) - limited evidence but frequently used; long-term antibiotic prophylaxis if non-antibiotic measures insufficient: nitrofurantoin 50-100 mg/evening or TMP-SMX 40/200 mg/evening × 6-12 months
- Simple acute pyelonephritis (female, no risk factors for complications): systematic ECBU before any antibiotic treatment + blood cultures if fever > 38.5°C or chills; outpatient treatment possible if mild to moderate acute pyelonephritis (no sepsis, no incoercible vomiting, no risk factors): ciprofloxacin 500 mg × 2/day × 7 days or TMP-SMX 160/800 mg × 2/day × 14 days (if sensitivity confirmed by ECBU); amoxicillin-clavulanate 875/125 mg × 3/day × 14 days (if sensitivity confirmed); ECBU check at 5-7 days of treatment recommended to confirm urinary sterilization
- Male UTI (prostatitis, orchi-epididymitis): any man with a urinary tract infection is considered to have a complicated UTI; ECBU + additional work-up (PSA, prostatic ultrasound depending on context); longer duration of antibiotic therapy (acute prostatitis: 14-28 days; chronic prostatitis: 4-6 weeks); quinolones or TMP-SMX for prostatic penetration; urological opinion for recurrences or complicated forms.
- UTI in pregnant women: systematic ECBU in 1st trimester (screening for asymptomatic bacteriuria) + if symptoms at any time; mandatory treatment of asymptomatic bacteriuria (≥ 10⁵ UFC/mL) - reduces risk of pyelonephritis by 30 % and premature delivery; safe antibiotics in pregnancy: amoxicillin-clavulanate, nitrofurantoin (avoid in 3rd trimester - risk of neonatal hemolytic anemia), cefalexin (Keflex); contraindications in pregnancy: fluoroquinolones, TMP-SMX (1st trimester - antifolate, 3rd trimester - neonatal jaundice), tetracyclines; follow-up ECBU 7 days after end of treatment
- Asymptomatic bacteriuria (BAS) - when not to treat: non-pregnant, non-diabetic, non-immunocompromised adult, no planned urological instrumentation → do not treat BAS; unnecessary treatment, increases resistance and side effects; on indwelling urinary catheter → do not treat unless symptoms, sepsis or surgical manipulation imminent; asymptomatic diabetic → do not treat (IDSA 2019 recommendations - treatment does not improve clinical outcomes); treat BAS only: pregnancy, before surgery or transrectal prostate biopsy, before urological stenting, recent kidney transplant (< 3 months), profound neutropenia
Signs of seriousness - urgent medical attention or 911
Dial 911 or go immediately to the emergency room if a urinary tract infection is accompanied by high fever (> 39°C) with chills, severe back pain, vomiting preventing oral antibiotics, confusion or altered consciousness, hypotension (low blood pressure) - these signs indicate severe pyelonephritis, bacteremia or urinary sepsis requiring hospitalization, blood cultures, IV antibiotic therapy and sometimes emergency urinary tract drainage if associated obstruction. Consult us immediately if you are pregnant with fever and back pain, if you have a single kidney or a kidney transplant, or if symptoms do not improve after 48 hours of antibiotic therapy.
For any urinary tract infection, urinary culture or ECBU result to be interpreted, Clinique Omicron doctors prescribe the appropriate treatment, ensure follow-up and refer to the urologist if necessary. Consultations are available in our Quebec branches, as well as via telemedicine. To book an appointment, visit cliniqueomicron.ca.
Consult at Clinique Omicron
Clinique Omicron prescribes and interprets ECBUs, initiates empirical antibiotic treatment adapted to local resistance profiles, manages recurrent urinary tract infections and male UTIs, and provides post-treatment follow-up monitoring. Screening for asymptomatic bacteriuria during pregnancy is included in the prenatal care offered by our doctors. Consultations are available in our Quebec branches, as well as via telemedicine. To book an appointment, visit cliniqueomicron.ca.
The content of this page is provided for information purposes only and does not replace the advice of a qualified healthcare professional. The interpretation of an ECBU must always be made in the complete clinical context of the patient.
Omicron Clinic
Need to consult a doctor?
Treatment within 24-48 hours. In-clinic or telemedicine, anywhere in Quebec.
Insurance receipts. 7j/7. No family doctor required.